What are the recent methods of cancer treatment by using immunotherapy?
Best insight from top research papers
Recent methods of cancer treatment using immunotherapy include adoptive cell therapy, cancer vaccines, cytokines, monoclonal antibodies, and immune checkpoint inhibitors. Adoptive cell therapy involves using T-lymphocytes expressing chimeric antigen receptors to treat hematological cancers . Cancer vaccines stimulate the immune system to target tumor-specific antigens on the surface of tumor cells . Cytokine therapy utilizes cytokines to enhance the immune response against cancer cells . Monoclonal antibodies can be used to target specific molecules involved in tumor growth and angiogenesis, such as vascular endothelial growth factor (VEGF) and immune checkpoint molecules like CTLA-4 and PD-1 . Immune checkpoint inhibitors, such as Ipilimumab, block inhibitory molecules like CTLA-4 or PD-1 to enhance the immune response against tumor cells . These recent methods of cancer treatment using immunotherapy aim to activate and enhance the immune system's ability to recognize and destroy tumor cells, providing promising clinical prospects .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The paper discusses the use of immunomodulatory drugs and monoclonal antibodies as recent methods of cancer treatment through cancer immunotherapy. | |
| The recent methods of cancer treatment using immunotherapy include immune checkpoint blockade therapy, adoptive cell therapy, cancer vaccine therapy, cytokine therapy, and oncolytic immunotherapy. | |
1 Citations | The recent methods of cancer treatment using immunotherapy include adoptive cell therapy, blockade of immune checkpoints, and the use of tumor vaccines and tumor-specific monoclonal antibodies. |
| The recent methods of cancer treatment using immunotherapy include cancer vaccines, adoptive cell therapy, cytokines, and monoclonal antibodies. | |
24 Mar 2023 | The paper discusses the use of monoclonal antibodies as an immunotherapy for cancer treatment, including Bevacizumab and immune checkpoint inhibitors like Ipilimumab. |
Related Questions
Cancer immunotherapy by targeting multiple Cancer antigens5 answersCancer immunotherapy targeting multiple cancer antigens has emerged as a promising strategy to enhance treatment efficacy. Various approaches such as peptide-based vaccines, cancer/testis antigens, and neoantigens derived from tumor-specific mutationshave shown potential in stimulating immune responses against cancer cells. By utilizing synthetic DNA vaccines targeting different prostate-specific antigens, broader and improved immunity against prostate cancer has been observed. However, resistance to traditional immunotherapy can arise due to upregulated expression of alternate immune checkpoints like VISTA, LAG-3, TIGIT, and TIM-3, emphasizing the importance of targeting multiple molecules on cancer and immune cells to overcome resistance and enhance treatment outcomes. Combinatorial targeting of traditional and alternate immune checkpoints may be beneficial for immune-refractory tumors, highlighting the significance of a multifaceted approach in cancer immunotherapy.
What is the recent trends in immunotherapy in cancer?5 answersRecent trends in immunotherapy in cancer include the rapid growth of research publications in the field. There has been a shift in focus from mechanism research to clinical trials, indicating that clinical application is becoming a central focus. Cancer immunotherapy has shown promising results in the treatment of various malignancies, leading to the development and approval of multiple immunotherapeutic approaches. Nanotechnology has played a significant role in improving treatment efficacy by enabling site-specific and sustained delivery of therapeutic agents for immunotherapy. Neoantigen-based cancer vaccines have emerged as a promising strategy, utilizing tumor-specific antigens to activate cytotoxic T cells. Immune checkpoint inhibitors, such as PD-L1 inhibitors, have demonstrated efficacy in a variety of tumors and are a well-known therapeutic class in immuno-oncology. Combination therapies, including the use of immunotherapy in conjunction with other treatment modalities, have shown improved clinical outcomes. Despite the success of immunotherapy, challenges remain, including managing side effects and the high cost of these therapies.
What is the current state of immunotherapy for solid tumors, cancer especially using engineered T-cell therapy?4 answersImmunotherapy for solid tumors, especially using engineered T-cell therapy, is still facing challenges. The limited responses in solid tumors can be attributed to difficulties in identifying target antigens that are uniformly expressed by tumor cells and absent in normal tissues, as well as the immunosuppressive tumor microenvironment (TME) that promotes immune escape. However, recent advancements in CAR-T cell design, such as incorporating co-stimulatory domains and developing armored CAR-T cells, have shown promise in treating solid tumors. Additionally, other immune cells like natural killer (NK) cells and macrophages (M) have been explored as potential options for cancer immunotherapy of solid tumors. Ongoing research is focused on improving the efficacy and safety of cellular therapies by combining them with immune checkpoint inhibitors or other agents targeting the cancer cell or the tumor environment. Clinical trials are underway to investigate the safety and efficacy of engineered immune cells, including CAR-T, CAR-NK, and CAR-M, for targeting solid tumors.
What are the most promising immunotherapies for cancer?5 answersThe most promising immunotherapies for cancer include monoclonal antibody therapies, adaptive immunotherapies, CAR T cells, T cell attracting bispecific antibodies, TCR mimic antibodies, and immune checkpoint inhibitors. These approaches have shown success in increasing the efficacy of the immune system in attacking cancer cells. Bispecific T cell attracting monoclonal antibody-mediated killing of cancer cells is particularly promising for novel effective cancer immunotherapies. Additionally, vaccines, including peptide and nucleic acid vaccines, as well as dendritic cell vaccines, are being developed as immunotherapy options. Other immunotherapeutic approaches such as adoptive cell therapies, cytokine therapies, and oncolytic viruses have also demonstrated promising clinical efficacy. Immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, have shown potential benefits in long-term survival and antitumor effects in a broad spectrum of malignancies. Overall, these immunotherapies offer new opportunities for effective cancer treatments.
What are the potential immunotherapies for treating cancer?5 answersImmunotherapies for treating cancer include adoptive cell therapies (ACTs) using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, checkpoint blockades, activating the immune system in a cytokine-dependent manner, manipulating feedback mechanisms involved in the immune response, enhancing the immune response via lymphocyte expansion, and using cancer vaccines to elicit long-lasting, robust responses. CAR T-cell immunotherapy is particularly effective in controlling cancer progression when combined with antibiotics or immunomodulation. Additionally, therapeutic approaches targeting the tumor microenvironment and involving immune cells, especially T cells, have shown promise in clinical trials. Manipulating cytokine-receptor pathways, particularly those related to tumor-associated regulatory T cells (Tregs), may also be a promising strategy for treating various malignancies.
What kinds of cancer currently have FDA approved immunotherapy treatments?2 answers